CLINICAL TRIALS PROFILE FOR INSULIN ZINC SUSP PROMPT BEEF
✉ Email this page to a colleague
All Clinical Trials for Insulin Zinc Susp Prompt Beef
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00467246 ↗ | Sub-Cutaneous Insulin in Hyperglycaemic Emergencies | Withdrawn | The Royal Bournemouth Hospital | N/A | 1969-12-31 | Hyperglycaemic emergencies are associated with significant mortality (mortality in Diabetic Ketoacidosis 0.65 - 3.3% and in HyperOsmolar Non-Ketotic Coma 12 -17%). To reduce morbidity and mortality, prompt intervention and coma and close monitoring are essential. The study is designed to investigate whether a simple intervention with a long acting insulin can improve resolution of acidosis and hyperglycaemia, prevent recurrence of ketoacidosis and shorten hospital stay. |
| NCT00657280 ↗ | Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure | Completed | Merck Sharp & Dohme Corp. | Early Phase 1 | 2008-04-01 | This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart. |
| NCT00657280 ↗ | Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure | Completed | Stanford University | Early Phase 1 | 2008-04-01 | This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart. |
| NCT01016509 ↗ | Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis | Completed | Second University of Naples | N/A | 2009-12-01 | A multicentric study will evaluate whether peri-procedural tight glycemic control during angioplasty revascularization for acute coronary syndrome (ACS) reduces circulating inflammatory cytokines and thrombus formation in hyperglycaemic patients. Moreover, the investigators will assess whether the tight glycemic control during the first month from coronary event reduces the incidence of coronary stent restenosis at 6-months from PCI. |
| NCT01016509 ↗ | Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis | Completed | University of Campania "Luigi Vanvitelli" | N/A | 2009-12-01 | A multicentric study will evaluate whether peri-procedural tight glycemic control during angioplasty revascularization for acute coronary syndrome (ACS) reduces circulating inflammatory cytokines and thrombus formation in hyperglycaemic patients. Moreover, the investigators will assess whether the tight glycemic control during the first month from coronary event reduces the incidence of coronary stent restenosis at 6-months from PCI. |
| NCT01070758 ↗ | Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy | Unknown status | Sheba Medical Center | Phase 4 | 2010-02-01 | The purpose of our study is to evaluate the efficacy and safety of Lanreotide Autogel in children with congenital hyperinsulinism already treated with Octreotide by pump. Congenital hyperinsulinism is a genetic disorder characterized by inappropriate insulin secretion resulting in persistent hypoglycemia (low blood sugars. Patients exposed to recurrent hypoglycemic episodes are at increased risk of developmental disorders, so identification and prompt management of patients are essential. Many patients are treated with the somatostatin analog Octreotide which is administered by continuous infusion using a pump (we use an insulin pump). This treatment may pose a huge burden and be stressful for patients and families as it demands intensive daily care. In an effort to simplify the daily care of our patients and improve their quality of life we will study the efficacy and safety of Lanreotide Autogel - a long-acting somatostatin analog that can be administered by injection once a month |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Insulin Zinc Susp Prompt Beef
Condition Name
Clinical Trial Locations for Insulin Zinc Susp Prompt Beef
Trials by Country
Clinical Trial Progress for Insulin Zinc Susp Prompt Beef
Clinical Trial Phase
Clinical Trial Sponsors for Insulin Zinc Susp Prompt Beef
Sponsor Name
